Table 4.

The results of univariate logistic regression analysis and multivariate logistic regression analysis of each variable in the training set

	Univariate logistic regression analysis		Multivariate logistic regression analysis
	OR(95%CI)	P	OR(95%CI)	P
Gender	2.83(0.98–8.15)	0.054
Age	0.77(0.31–1.90)	0.57
HBsAg	0.29(0.06–1.52)	0.144
TBiL	3.20(0.93–11.02)	0.065
DBiL	1.33(0.35–5.15)	0.677
IBiL	3.10(0.99–9.71)	0.052
TP	1.69(0.51–5.60)	0.390
ALB	0.97(0.39–2.41)	0.943
GGT	2.00(0.80–5.02)	0.140
AST	12.75(2.70–60.16)	0.001*	9.73(1.89–50.04)	0.006*
ALT	12.42(1.52–101.68)	0.019*	4.89(0.49–48.60)	0.176
ALP	7.62(1.59–36.59)	0.011*	7.52(1.43–39.54)	0.017*
PA	2.10(0.46–9.46)	0.336
AFP	2.10(0.85–5.19)	0.110
CA199	2.07(0.73–5.89)	0.172
CEA	0.38(0.09–1.67)	0.201
Number of tumors	2.48(0.78–7.89)	0.124
Tumor size	5.80(2.18–15.45)	< 0.001*	2.95(0.97–8.98)	0.057
Peritumoral satellite lesions	3.00(0.75–12.08)	0.122
Tumor margin	7.35(1.89–28.54)	0.004*	3.64(0.84–15.83)	0.085
Tumor capsule	1.26(0.76–2.10)	0.367
Intratumoral necrosis	1.88(1.14–3.11)	0.013*
Bile duct dilatation	1.60(0.43–5.98)	0.485
Tumor enhancement	2.99(1.22–7.34)	0.017*
Peritumoral enhancement in arterial phase	5.50(1.90–15.96)	0.002*	2.63(0.80–8.67)	0.113
Large vein invasion	4.40(1.13–17.11)	0.033*
lymph node enlargement	143,564,018.56(0– + ∞)	0.992
MVI	3.34(1.31–8.55)	0.012*	3.34(1.31–8.55)	0.012*
Hepatocyte	1.41(0.52–3.84)	0.504
Glypican3	1.43(0.46–4.42)	0.536
CD34	0.93(0.23–3.74)	0.913
CK19	5.13(0.55–48.12)	0.153
Ki67	2.13(0.75–5.99)	0.154

OR odds ratio; CI confidence interval

*means P < 0.05